Dr. Thomas Martin on Cilta-Cel in the CARTITUDE-1 Study

What is the background of this study? 

Patients with relapsed refractory multiple myeloma (RRMM) who are triple-class exposed (to immunomodulatory drugs [IMiDs], proteasome inhibitors [PIs] and an anti-CD38 antibody) cycle through multiple salvage regimens with progressively worse outcomes. CARTITUDE-1 (NCT03548207) is a single-arm phase Ib/2 study evaluating cilta-cel, a chimeric antigen receptor T-cell therapy with 2 B-cell maturation antigen–targeting single-domain antibodies. The study observes patients with RRMM who received ≥3 prior lines of therapy or were double refractory to an IMiD and PI, were triple-class exposed, had ECOG score of 0 or 1, and had disease progression ≤12 months after the last line of therapy. 

In this video: 

Dr. Thomas G. Martin (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA) explains that this study compares efficacy outcomes for patients who received cilta-cel in CARTITUDE-1 (N = 97) with patients treated with standard-of-care in a synthetic cohort from real-world clinical practice. 

Conclusions:

Cilta-cel shows significantly better efficacy outcomes over real-word standard-of-care for progression-free survival and overall survival, highlighting its potential as an effective treatment option in patients with triple-class exposed RRMM. 

Clinical trial information: NCT03548207